Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$27,000.00

Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy in Alveolar Soft Part Sarcoma through Extrinsic and Intrinsic Inhibition of the PD1/PDL1 Immune Checkpoint Axis

FY 2024-25

Summary
Background Alveolar soft part sarcoma (ASPS) is a highly metastatic cancer that is poorly managed by traditional treatment approaches. A new strategy known as chimeric antigen receptor (CAR) T cell therapy, where specialized killing cells of a patient immune system called T cells are engineered to selectively target their cancer, has proven effective. In a first-in-human trial, a CAR T therapy developed by our lab successfully eliminated many metastatic growths in a patient with ASPS; however, larger growths were non-responsive, likely due to activation of immune checkpoints by the cancer that suppress T cell activity. Further analysis of a non-responsive growth identified PDL1 as a highly expressed checkpoint protein, which sends inhibitory signals through interactions with its receptor, PD1, on T cells. Interestingly, atezolizumab, a PDL1 inhibitor, was recently approved for treating ASPS and may augment CAR T therapy. Enhancing CAR T Therapy with atezolizumab: In an ASPS mouse model, my initial findings show improved anti-tumour activity using CAR T therapy in combination with atezolizumab. Since it is unclear how long after CAR T therapy atezolizumab treatment should begin, I will investigate and determine optimal atezolizumab dose timing.Aim 2 - Armouring CAR T Therapy against the PD1/PDL1 inhibitory pathway: I will develop an enhanced version of our CAR T therapy by reducing its sensitivity to PD1/PDL1-mediated inhibition in the absence of atezolizumab. To do so, I will overexpress a non-functional PD1 receptor on CAR T cells that outcompetes and thus blocks functional PD1 from receiving inhibitory signals.Significance This research will provide strong insights into strategies for enhancing CAR T therapy through blockade of PD1/PDL1 signalling.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529720
Name
Louie Taye
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy in Alveolar Soft Part Sarcoma through Extrinsic and Intrinsic Inhibition of the PD1/PDL1 Immune Checkpoint Axis
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alveolar Soft Part Sarcoma; Chimeric Antigen Receptor (Car) T Cell Therapy; Immune Checkpoint Inhibition; Pd1/Pdl1 Checkpoint Axis; Tumour Microenvironment
Abstract
Background Alveolar soft part sarcoma (ASPS) is a highly metastatic cancer that is poorly managed by traditional treatment approaches. A new strategy known as chimeric antigen receptor (CAR) T cell therapy, where specialized killing cells of a patient immune system called T cells are engineered to selectively target their cancer, has proven effective. In a first-in-human trial, a CAR T therapy developed by our lab successfully eliminated many metastatic growths in a patient with ASPS; however, larger growths were non-responsive, likely due to activation of immune checkpoints by the cancer that suppress T cell activity. Further analysis of a non-responsive growth identified PDL1 as a highly expressed checkpoint protein, which sends inhibitory signals through interactions with its receptor, PD1, on T cells. Interestingly, atezolizumab, a PDL1 inhibitor, was recently approved for treating ASPS and may augment CAR T therapy. Enhancing CAR T Therapy with atezolizumab: In an ASPS mouse model, my initial findings show improved anti-tumour activity using CAR T therapy in combination with atezolizumab. Since it is unclear how long after CAR T therapy atezolizumab treatment should begin, I will investigate and determine optimal atezolizumab dose timing.Aim 2 - Armouring CAR T Therapy against the PD1/PDL1 inhibitory pathway: I will develop an enhanced version of our CAR T therapy by reducing its sensitivity to PD1/PDL1-mediated inhibition in the absence of atezolizumab. To do so, I will overexpress a non-functional PD1 receptor on CAR T cells that outcompetes and thus blocks functional PD1 from receiving inhibitory signals.Significance This research will provide strong insights into strategies for enhancing CAR T therapy through blockade of PD1/PDL1 signalling.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Louie, Taye
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~